Companies / AI company
Recursion Pharmaceuticals
A drug discovery company that licenses Tempus's de-identified oncology records. Recorded here: 1 disclosed licensing deal and 1 public price.
recursion.comLatest record 21 Sep 2026
licensing deals
Public prices involving Recursion Pharmaceuticals
- Access to Tempus's de-identified multimodal oncology patient records for drug discovery, five-year licence to Recursion
The buyer's own filing. Multimodal clinical, molecular and imaging records rather than images alone; Recursion paid a $22.0 million initial fee plus these annual fees, up to $160.0 million over the term.
The payer's own page, Recursion Pharmaceuticals, Form 10-K for 2025 (SEC), note on the Tempus agreement
annual license fees ranging between $22.0 million and $42.0 millionper year of a five-year term (up to $160.0 million in total)
Licensing deals
- Sep 2026Tempus AI to Recursion Pharmaceuticals$42M
Not stated
In the same deals and cases
Cite this
AIData.Broker, “Recursion Pharmaceuticals in the AI training data market”, reviewed 21 Sep 2026. https://www.aidata.markets/companies/recursion-pharmaceuticals
Free to reuse under CC BY 4.0 if you credit AIData.Broker and link to this page. Each row names the publication that stated it, and words quoted from a source keep that source's own terms.